Last reviewed · How we verify

Neostigmine and Glycopyrrolate

James J. Peters Veterans Affairs Medical Center · FDA-approved active Small molecule

Neostigmine and Glycopyrrolate is a Cholinesterase inhibitor with anticholinergic agent Small molecule drug developed by James J. Peters Veterans Affairs Medical Center. It is currently FDA-approved for Myasthenia gravis, Reversal of neuromuscular blockade (anesthesia). Also known as: Glycostigmin..

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects. Used for Myasthenia gravis, Reversal of neuromuscular blockade (anesthesia).

At a glance

Generic nameNeostigmine and Glycopyrrolate
Also known asGlycostigmin.
SponsorJames J. Peters Veterans Affairs Medical Center
Drug classCholinesterase inhibitor with anticholinergic agent
TargetAcetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Neostigmine is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, thereby enhancing neuromuscular transmission and parasympathetic activity. Glycopyrrolate is an anticholinergic agent added to this combination to block unwanted muscarinic effects (such as excessive salivation, bronchospasm, and bradycardia) that would otherwise result from neostigmine monotherapy. Together, they provide the therapeutic benefits of cholinergic enhancement while mitigating parasympathomimetic adverse effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Neostigmine and Glycopyrrolate

What is Neostigmine and Glycopyrrolate?

Neostigmine and Glycopyrrolate is a Cholinesterase inhibitor with anticholinergic agent drug developed by James J. Peters Veterans Affairs Medical Center, indicated for Myasthenia gravis, Reversal of neuromuscular blockade (anesthesia).

How does Neostigmine and Glycopyrrolate work?

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.

What is Neostigmine and Glycopyrrolate used for?

Neostigmine and Glycopyrrolate is indicated for Myasthenia gravis, Reversal of neuromuscular blockade (anesthesia).

Who makes Neostigmine and Glycopyrrolate?

Neostigmine and Glycopyrrolate is developed and marketed by James J. Peters Veterans Affairs Medical Center (see full James J. Peters Veterans Affairs Medical Center pipeline at /company/james-j-peters-veterans-affairs-medical-center).

Is Neostigmine and Glycopyrrolate also known as anything else?

Neostigmine and Glycopyrrolate is also known as Glycostigmin..

What drug class is Neostigmine and Glycopyrrolate in?

Neostigmine and Glycopyrrolate belongs to the Cholinesterase inhibitor with anticholinergic agent class. See all Cholinesterase inhibitor with anticholinergic agent drugs at /class/cholinesterase-inhibitor-with-anticholinergic-agent.

What development phase is Neostigmine and Glycopyrrolate in?

Neostigmine and Glycopyrrolate is FDA-approved (marketed).

What are the side effects of Neostigmine and Glycopyrrolate?

Common side effects of Neostigmine and Glycopyrrolate include Dry mouth, Blurred vision, Tachycardia, Muscle fasciculations, Increased intraocular pressure.

What does Neostigmine and Glycopyrrolate target?

Neostigmine and Glycopyrrolate targets Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate) and is a Cholinesterase inhibitor with anticholinergic agent.

Related